Quimatryx is devoted to the Discovery and Development of novel drugs against epigenetic targets focused on the area of cancer. Quimatryx Ltd has designed a best in class HDAC6 selective inhibitor, QTX125, with the aim of reducing the side effects of the treatment and beating the therapeutic activit... Read more
This company has no teams yet
This company has no offices yet